

DRAFT landscape of COVID-19 candidate vaccines –
7 July 2020 21 candidate vaccines in clinical evaluation

Platform	Type of candidate vaccine	Developer	Current stage of clinical evaluation/regulatory status-Coronavirus candidate	Same platform for non-Coronavirus candidates	Administration route
Inactivated	Inactivated + alum	Sinovac	Phase 3 NCT04456595 Phase 1/2 NCT04383574 NCT04352608	SARS	Intramuscular
Non-Replicating Viral Vector	ChAdOx1-S	University of Oxford/AstraZeneca	Phase 3 SRCTN89951424 Phase 2b/3 2020-001226-32 Phase 1/2 PACT R202006922165132 2020-001072-15	MERS, influenza, TB, Chikungunya, Zika, MarB, plague	Intramuscular
Non-Replicating Viral Vector	Adenovirus Type 5 Vector	CanSino Biological Inc./Beijing Institute of Biotechnology	Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906	Ebola	Injection (not specified)
RNA	LNP-encapsulated mRNA	Moderna/NIAID	Phase 2 NCT04405076 Phase 1 NCT04282461	multiple candidates	Intramuscular
DNA	DNA plasmid vaccine with electroporation	Novio Pharmaceuticals/International Vaccine Institute	Phase 1/2 NCT04447781 NCT04336410	multiple candidates	Electroporation
DNA	DNA plasmid vaccine	Cadila Healthcare Limited	Phase 1/2 CTRI/2020/07/026352 (not yet recruiting)		Intradermal
Inactivated	Inactivated	Wuhan Institute of Biological Products/Sinopharm	Phase 1/2 ChiCTR2000031809		
Inactivated	Inactivated	Beijing Institute of Biological Products/Sinopharm	Phase 1/2 ChiCTR2000032450		
Protein Subunit	Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M	Novavax	Phase 1/2 NCT04368988	RSV, CCHF, HPV, VZV, EBOV	Intramuscular
RNA	3 LNP-mRNAs	BioNTech/Fosun Pharma/Pfizer	Phase 1/2 2020-001038-36 NCT04368728		Intramuscular
DNA	DNA Vaccine (GX-19)	Genexine Consortium	Phase 1 NCT04445389		Intramuscular
DNA	DNA plasmid vaccine + Adjuvant	Osaka University/ AnGes/ Takara Bio	Phase 1 JapicCTI-205328		
Inactivated	Inactivated	Institute of Medical Biology, Chinese Academy of Medical Sciences	Phase 1 NCT04412538		
Non-Replicating Viral Vector	Adeno-based	Gamaleya Research Institute	Phase 1 NCT04436471 NCT04437875		Intramuscular
Protein Subunit	Native like Trimeric subunit Spike Protein vaccine	Clover Biopharmaceuticals Inc./GSK/Dynavax	Phase 1 NCT04405908	HIV, REV influenza	Intramuscular
Protein Subunit	Adjuvanted recombinant protein (RBD- Dimer)	Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences	Phase 1 NCT04445194	MERS	Intramuscular
Protein Subunit	Recombinant spike protein with Adva TM adjuvant	Vaxine Pty Ltd/Medytox	Phase 1 NCT04453852		Intramuscular
RNA	LNP-nCoVsaRNA	Imperial College London	Phase 1 ISRCTN17072692	EBOV, LASV, MARV, hif (H7N9), RABV	Intramuscular
RNA	mRNA	Curevac	Phase 1 NCT04449276	RABV, LASV, YFV; MERS, hifA, ZIKV, DENV, NIPV	Intramuscular
RNA	mRNA	People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.	Phase 1 ChiCTR2000034112		
VLP	Plant-derived VLP	Medicago Inc./ Université Laval	Phase 1 NCT04450004 (not yet recruiting)	Flu, Rotavirus, Norovirus, West Nile virus, Cancer	Intramuscular